Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
  • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
  • A61K9/2846—Poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• compositions comprising indigo and/or an indigo derivative, such as indirubin, and to methods of treatment, including the treatment of inflammatory bowel diseases.
• Indigo naturalis is a plant extract prepared from the plants Indigofera tinctoria, Indigofera suffruticosa, Polygonum tinctorium, and/or Jsa/is indigotica.
• An exemplary Indigo naturalis composition is an extract of Baphicacanthus cusia (Nees) Bremek of the Acanthacaea family.
• Indigo naturalis is composed of multiple compounds known to activate the aryl hydrocarbon receptor. Bespoke compositions offering the benefits of Indigo naturalis with optimized clinical efficacy and safety are desired.
• oral dosage forms with one or more of the active components of Indigo naturali such as the indigo derivative indirubin, are desired.
• indigo and indirubin are potent agonists of the aryl hydrocarbon receptor. Indigo is less potent than indirubin at activating the aryl hydrocarbon receptor, requiring more drug to achieve the same effect. Both compounds have poor aqueous dissolution and solubility, making it difficult to formulate suitable pharmaceutical dosage forms. Also, the limited dissolution and solubility of indirubin presents drug delivery challenges especially when targeting local drug delivery to the gastro-intestinal tract.
• Mechanisms to make indirubin locally but not systemically bioavailable are desired for the treatment of inflammatory bowel diseases.
• Methods to activate the AhR in the colon or intestine, but not systemically in organs such as the liver or lungs, may minimize potential side effects like changes in liver enzymes and the development of pulmonary arterial hypertension.
• composition comprising a compound selected from indigo, an indigo derivative, and combinations thereof and a pharmaceutically acceptable carrier is provided.
• the composition provides a therapeutic effect with respect to treating ulcerative colitis that is substantially the same as provided by a composition of Indigo naturalis.
• the composition provides a synergistic or a superior therapeutic effect with respect to treating ulcerative colitis as compared to the effect provided by a composition of Indigo naturalis.
• the composition provides a reduction in observed side effects compared to the side effects observed following administration of Indigo naturalis.
• the composition provides a synergistic effect with respect to treating ulcerative colitis as compared to the effect provided by a composition of the carrier and indigo or an indigo derivative individually.
• the composition comprises a compound selected from indigo, indirubm, isatin, and combinations thereof. In one embodiment, the composition comprises only or solely active therapeutic compound selected from indigo and indigo derivatives, or selected from indigo, indirubin, isatin, and combinations thereof.
• the composition is not Indigo naturalis , the known plant extract.
• the compound in the composition is synthetically produced.
• the compound is obtained from a plant extract or wherein the compound is within or part of a plant extract.
• the composition comprises solely or only indigo, indirubin or isatin. In another embodiment, the composition comprises solely or only an indigo derivative.
• a dosage form is provided that is comprised of a solid dispersion of an aryl hydrocarbon receptor agonist and a polymenc hydrophilic carrier, wherein aryl hydrocarbon receptor agonist is in a substantially amorphous form in the dispersion.
• a formulation is provided that is comprised of a solid dispersion of an aryl hydrocarbon receptor agonist and a polymeric hydrophilic carrier, wherein aryl hydrocarbon receptor agonist is in a substantially amorphous form in the dispersion; and one or more excipients in an amount greater than about 20 wt% of the formulation and blended with the solid dispersion to form a blend.
• the one or more excipients is/are present in the formulation in an amount greater than about 25 wt%, 30 wt%, 35 wt%, 40 wt%, 45 wt%, 50 wt%, 55 wt%, 60 wt%, 65 wt% or 70 wt%.
• the aryl hydrocarbon receptor is natural indirubin or synthetic indirubm.
• the dispersion comprises between about 0.1-30 wt%, 0.5-30 wt%, 0.5-25 wt%, 0.5-20 wt%, 0.5-15 wt%, 1-25 wt%, 1-20 wt%, 2-25 wt%, 2-20 wt% or 2015 wt% or 2-10 wt% of the aryl hydrocarbon receptor, such as natural or synthetic indirubin.
• the dispersion comprises a ratio of polymeric hydrophilic carrier to indirubin of 10: 1 to 50: 1. In another embodiment, the dispersion comprises a ratio of polymeric hydrophilic carrier to indirubin of 10:1 to 25:1.
• the polymeric hydrophilic carrier is a cellulosic polymer, a cellulosic copolymer, a polyvinyl acetate polymer, a polyvinyl acetate-polyethylene glycol copolymer, a methacrylic acid copolymer, a methacrylic acid-methyl methacrylate copolymer, a polyvinyl pyrrolidone polymer, a polyvinyl pyrrolidone copolymer, a polyvinyl alcohol polymer, or a polyvinyl alcohol copolymer.
• the cellulosic polymer is a synthetic cellulosic polymer selected from hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose and carboxymethyl ethylcellulose.
• the methacrylic acid-methyl methacrylate copolymer is a 1:2 or a 1 : 1 copolymer of methacrylic acid and methyl methacrylate.
• the cellulosic polymer is selected from cellulose acetate phthalate and hydroxypropyl methylcellulose phthalate.
• the polymeric hydrophilic carrier dissolves or becomes soluble at a pH between 4.5-7 5 in the intestinal tract or in simulated gastric fluid at a temperature of 25°C or 30°C or 35°C.
• the polymeric hydrophilic carrier dissolves or becomes soluble at a pH between 4.5-7.5 and is insoluble at pH 1.5-3.5 in the intestinal tract or in simulated gastric fluid at a temperature of 25°C or 30°C or 35°C.
• the dosage form or the formulation achieves one or more of (i) the release of substantially all of the indirubin from the dosage form in the small intestine, large intestine and/or colon; and (ii) the release of substantially all indirubin from the dosage form within about 60 minutes when at a pH above 5; (iii) the release of substantially all of the indirubin from the dosage form over a period of about 8 hours when at a pH of above 5
• one or more of (i), (ii) or (iii) is achieved without use of an enteric polymer coating on the outside of the dosage form.
• one or more of (i), (ii) or (iii) is achieved with the use of an enteric polymer coating on the outside of the dosage form.
• the dispersion has an indirubin solubility in simulated intestinal fluid greater than a dispersion containing the same amount of indirubin in the form of crystalline mdirubin, Indigo naturalis or a 1:9 povidone: indirubin solid dispersion in simulated intestinal fluid, at the same temperature.
• the indirubin remains in a substantially amorphous form the dispersion for at least about 6 months when stored at 25°C.
• the dispersion does not contain indigo, and/or wherein the dosage form does not contain indigo.
• the hydrophilic carrier is not hypromellose acetate succinate and/or wherein the solid dispersion is not produced via precipitation from dimethylacetamide.
• the polymeric hydrophilic carrier is not povidone.
• the dosage form or the formulation when administered it provides a therapeutic effect with respect to treating ulcerative colitis that is equal or superior to the therapeutic effect provided by an oral composition of Indigo naturalis containing an equivalent amount of indirubin.
• the dosage form or formulation when administered it provides a reduction in observed side effects compared to the side effects obser ed following administration of Indigo naturalis.
• the dosage form or formulation is suitable for localized delivery.
• the localized delivery via oral administration to the small intestine or colon.
• the localized delivery is topical delivery to intact or disrupted oral mucosa.
• the localized delivery is topical delivery to the rectum or colon.
• the dosage form or formulation yields a non-therapeutic blood level of indirubin.
• the dosage form or formulation yields a systemic blood level of less than about 1 nM of the compound.
• the dosage form, or the formulation is a tablet, a capsule, a gel cap, an enteric-coated tablet, an enteric-coated tablet capsule, an enteric-coated gel cap, a collection of microspheres, a collection of nanoparticles, a suspension, a powder for suspension, an orally-disintegrating tablet, a buccal tablet, an orally-dissolving film, a lozenge, a suppository, foam, an enema, an ointment, a cream, or a gel.
• the one or more excipients is selected from the group consisting of a disintegrant, a filler, a surfactant, and a lubricant.
• the formulation or dosage form comprises a carrier that is suitable for oral administration.
• the carrier is a polymer that provides for release of a majority of the compound or of at least two compounds in the colon or in the stomach or in the small intestine.
• the polymer is a pH-sensitive polymer.
• the polymer solubility increases with increasing pH.
• Exemplary polymers are polyvinyl polymers, cellulosic polymers, polyvinyl-polyethylene glycol copolymers, methacrylic acid copolymers, and methacrylic acid-methyl methacrylate copolymers.
• the copolymer can be a 1 :2 or a 1 :1 copolymer of methacrylic acid and methyl methacrylate.
• the cellulosic polymer can be selected from cellulose acetate phthalate and hydroxypropyl methylcellulose phthalate.
• the polymer is a biodegradable polymer.
• An example is a polymer that degrades in the presence of hydrolytic or metabolizing enzymes, such as a polysaccharide or an azo-aromatic polymer.
• the polysaccharide is selected from chitosan, guar gum, xanthan gum, dextran, pectin, amylose, inulin, chondroitin sulfates, and derivatives thereof.
• the azo-aromatic polymer is prepared from a monomer selected from the group consisting of acrylic acid, butyl methacrylate, methyl methacrylate, styrene, and hydroxyethyl methacrylate.
• the azo aromatic polymer is a copolymer of two or more of the monomers.
• the polymer is a bioadhesive / gastroretentive polymer or a hydrogel.
• the bioadhesive / gastroretentive polymer is selected from the group consisting of polycarbophils, polyurethanes, and polyethylene oxides.
• the compound or at least two compounds are formulated alone or with a carrier into particles or granules.
• the particles or granules in one embodiment, comprise a population of particles or granules with a size distribution tailored to achieve delayed or extended release of the compound(s).
• the polymers allow for immediate or slow release of the active agents.
• the polymer is selected from a group consisting of alginates, cyclodextrins, polyglycolides or polylactides.
• the formulation contains a penetration enhancer to allow for penetration into the intestinal tissue or through the intestinal tissue into the blood stream.
• the carrier is suitable for rectal administration.
• the carrier is suitable for topical administration.
• exemplary topical compositions include, but are not limited to, a gel, a suspension, a lozenge, a cream, a foam, a suppository, an enema or an ointment.
• a method for treating ulcerative colitis comprises administering to a subject a therapeutically effective amount of a composition comprising indigo, indirubin, isatin, or a combination thereof, wherein the composition is not Indigo naturalis , whereby the administering treats UC in the subject.
• a method for treating inflammatory bowel disease in a subject comprises administering to a subject a therapeutically effective amount of a composition comprising indigo, indirubin, isatin, or a combination thereof, wherein the composition is not Indigo naturalis, whereby the administering treats the inflammatory bowel disease in the subject.
• the inflammatory bowel disease is not Crohn’s disease.
• a method for preventing recurrence of UC comprises administering to a subject a therapeutically effective amount of a composition comprising indigo, indirubin, isatin, or a combination thereof, wherein the composition is not Indigo naturalis , whereby the administering prevents recurrence of UC in the subject.
• a method for treating UC in a subject previously treated with 5- aminosalicylic acid or a prodrug of 5-aminosalicyline acid comprises administering to a subject a therapeutically effective amount of a composition comprising indigo, indirubin, isatin, or a combination thereof, wherein the composition is not Indigo naturalis , whereby the
• small molecule immunosuppressants e..
• the method comprises administering to a subject a therapeutically effective amount of a composition comprising indigo, indirubin, isatin, or a combination thereof, wherein the composition is not Indigo naturalis , whereby the administering treats UC in the subject.
• a method for treating mild to moderate UC in a subject refractory to treatment with 5-aminosalicylic acid or a prodrug of 5-aminosalicyline acid, the patient untreated with an anti-TNF-alpha antibody comprises administering to a subject a
• composition comprising indigo, indirubin, isatin, or a combination thereof, wherein the composition is not Indigo naturalis, whereby the
• the subject has moderate to severe UC. In other embodiments, the subject has mild to moderate UC. In other embodiments, the subject has mild to moderate Crohn’s disease or moderate to severe Crohn’s disease. In other embodiments the subject has gastrointestinal graft-vs-host disease, pouchitis, or mucositis.
• treatment re-sensitizes the subject to be responsive to previously failed or ineffective therapies.
• FIGS. 1A-1B are images of solid dispersions of synthetic indirubin and a hydrophilic polymer, polyvinylpyrrolidone, where the indirubin is not amorphous.
• FIGS. 2A-2B are images of amorphous solid dispersions of of synthetic indirubin and a hydrophilic polymer, polyvinylpyrrolidone.
• FIG. 3A is an x-ray diffractogram of the empty zero background sample holder, as a reference.
• FIG. 3B is an x-ray diffractogram for 100% crystalline Indirubin (at a concentration equivalent to 10% drug load samples), as a comparative reference.
• FIG. 3C is an x-ray diffractogram of a dispersion of 10% indirubin in PVP (povidone).
• FIG. 3D is an x-ray diffractogram of a dispersion of 5% indirubin in PVP.
• FIG. 3E is an x-ray diffractogram of a dispersion of 10% indirubin in
• FIG. 3F is an x-ray diffractogram of a dispersion of 5% indirubin in
• FIG. 3G is an x-ray diffractogram of a dispersion of 10% indirubin in hydroxypropyl methylcellulose acetate succinate (HPMC-AS).
• FIG. 3H is an x-ray diffractogram of a dispersion 5% indirubin in hydroxypropyl methylcellulose acetate succinate (HPMC-AS).
• FIG. 31 is an x-ray diffractogram of a dispersion of 10% indirubin in
• HPMCP hydroxypropylmethylcellulose phthalate
• FIG. 3J is an x-ray diffractogram of a dispersion of 5% indirubin in
• HPMCP hydroxypropylmethylcellulose phthalate
• FIG. 3K is an x-ray diffractogram of a dispersion of 10% indirubin in polyvinyl acetate phthalate (PVAP).
• FIG. 3L is an x-ray diffractogram of a dispersion of 5% indirubin in polyvinyl acetate phthalate (PVAP).
• FIG. 3M is an x-ray diffractogram of a dispersion of 10% indirubin in PVAc-PVCap- PEG, (SOLUPLUS ® ).
• FIG. 4 is a graph showing the fold improvement in activation of the human AhR in vitro for indimbin, indigo and Indigo naturalis as a function of concentration, in ng/mL.
• compositions of the present disclosure can comprise, consist essentially of, or consist of, the components disclosed.
• A“dispersion” refers to an admixture or system of particles of one material essentially homogeneously dispersed in a continuous phase of a second material.
• the particles are drug (active agent) particles and the second material is a polymer, such as a copolymer of methacrylic acid.
• indigo generally refers to a compound having the formula below identified as“indigo.”
• an“indigo derivative” refers to derivatives of indigo such as those exemplified by the compounds identified below as leuco-indigo, indimbin, meisoindigo, and isatin (an oxidized version of half of the indigo molecule):
• indigo derivatives include thioindigo, indigo carmine, indirubm-3’ -monoxime, indirubin-5-sulphonic acid or 5-chloro-indimbin, bromoindirubin-3- oxime, 5-halogenoindirubin, N-ethyl-indirubin, N-methylisoindigo, the compounds set forth in U.S. Patent Application Publication No. 2017/0304381, which is incorporated by reference herein, the compounds set forth in Hubbard, T.D. et al, Drug Metabolism and Disposition,
• Indigo naturalis refers to a plant extract that contains indigo and other indigo derivatives. This extract can be crude or highly purified to enrich for indigo and/or an indigo derivative.
• the plant extract can be from the species Indigofera tinctoria, Indigofera suffruticosa, Polygonum tinctorium, Isatis indigotica , Baphicacanthus cusia or other plants or yeast or bacteria that contain indigo.
• inhibiting or reducing are used in reference to methods to inhibit or to reduce a clinical symptom of a disorder in a population with the disorder as compared to an untreated, control population of subjects with the disorder.
• phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, salts, compositions, dosage forms, etc., which are--within the scope of sound medical judgment-suitable for use in contact with the tissues of human beings and/or other mammals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
• pharmaceutically acceptable means approved by a regulatory agency of the federal or a state government, or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals (e g., animals), and more particularly, in humans.
• Pharmaceutically acceptable salt denotes a salt form of a drug or active ingredient, or other ingredient having at least one group suitable for salt formation that causes no significant adverse toxicological effects to the patient.
• Reference to an AhR agonist compound, such as indirubin, is meant to encompass its pharmaceutically acceptable salts, as well as solvates and hydrates thereof.
• Pharmaceutically acceptable salts include salts prepared by reaction with an inorganic acid, an organic acid, a basic amino acid, or an acidic amino acid, depending upon the nature of the functional group(s) in the drug.
• Suitable pharmaceutically acceptable salts include acid addition salts which may, for example, be formed by mixing a solution of a basic drug with a solution of an acid capable of forming a pharmaceutically acceptable salt form of the basic dmg, such as hydrochloric acid, iodic acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, sulfuric acid and the like.
• Typical anions for basic drugs when in protonated form, include chloride, sulfate, bromide, mesylate, maleate, citrate and phosphate.
• Suitable pharmaceutically acceptable salt forms and methods for identifying such salts are found in, e.g., Handbook of Pharmaceutical Salts: Properties, Selection and Use, Weinhei m/Zurich: Wiley-VCH/VHC A. 2002; P. H. Stahl and C. G. Wermuth, Eds.
• pharmaceutically acceptable carrier refers to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions described herein without causing a significant adverse toxicological effect on the patient.
• pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors, and the like.
• a“pH sensitive coating” is a layer applied to or enclosing a capsule or tablet that is stable in one pH range, yet becomes unstable, or permeable, or soluble, in another pH range.
• many pH sensitive coatings are insoluble at low pH (e.g., near pH 3) yet become more soluble at higher pH (e.g., above pH 5 or 6).
• Such a coating may also be termed an“enteric coating”.
• the terms "patient” or “subject” refers to a living organism suffering from or prone to a condition that can be treated by administration of a pharmaceutical compositions as provided herein.
• Non-limiting examples include humans, other mammals and other non-mammalian animals.
• substantially or “essentially” means nearly totally or completely, for instance, 95% or greater, of a given quantity.
• treating is used herein, for instance, in reference to methods of treating an inflammatory disorder, and generally includes the administration of a compound or composition which reduces the frequency of, or delays the onset of, symptoms of the medical condition (e.g., UC) in a subject relative to a subject not receiving the compound or composition. This can include reversing, reducing, or arresting the symptoms, clinical signs, and underlying pathology of a condition in a manner to improve or stabilize a subject's condition.
• a compound or composition which reduces the frequency of, or delays the onset of, symptoms of the medical condition (e.g., UC) in a subject relative to a subject not receiving the compound or composition. This can include reversing, reducing, or arresting the symptoms, clinical signs, and underlying pathology of a condition in a manner to improve or stabilize a subject's condition.
• topical composition refers to a matenal that comprises pharmaceutically acceptable ingredients, including an active indigo agent, and is intended for administration to an animal or human subject and is applied to the surface of the skin or to the mucosa of the oral cavity, small intestine or colon, in contrast to materials that are taken orally in order to achieve systemic exposure or via intravenous (subdermal) injection.
• a topical composition is generally intended to have its intended effect at the site of application and does not result in significant concentrations of drug in the bloodstream or other tissues (as is the case with, for example, transdermal compositions).
• Topical compositions as provided herein may be administered for the purpose of alleviation of symptoms associated with a gastrointestinal disorder or dermatological diseases or conditions, for the treatment of a gastrointestinal disorder or dermatological diseases or conditions, or for prevention of a gastrointestinal disorder or dermatological diseases or conditions.
• compositions of the present disclosure can comprise, consist essentially of, or consist of, the components disclosed.
• the components disclosed By reserving the right to proviso out or exclude any individual members of any such group, including any sub-ranges or combinations of sub-ranges within the group, that can be claimed according to a range or in any similar manner, less than the full measure of this disclosure can be claimed for any reason. Further, by reserving the right to proviso out or exclude any individual substituents, analogs, compounds, ligands, structures, or groups thereof, or any members of a claimed group, less than the full measure of this disclosure can be claimed for any reason.
• compositions comprised of indigo and/or an indigo derivative and an acceptable carrier are provided.
• the composition comprises one or more of indigo, indirubin, and/or isatin.
• the composition can be an extract that is enriched in one or more of indigo or an indigo derivative, such as indirubin and/or isatin.
• the composition is comprised of one or more of a synthetically manufactured indigo and/or an indigo derivative.
• the composition comprises a solid amorphous dispersion of a synthetically manufactured indigo and/or an indigo derivative, such as indirubin, and a hydrophilic polymer carrier.
• compositions described herein are comprised of a compound selected from indigo or an indigo derivative and a pharmaceutically acceptable carrier are provided.
• Indigo derivatives include, for example, indirubin and isatin.
• Some indigo derivatives exist as one or more isomers. For example, the (Z) isomer of indirubin, (Z)-2,3’-Biindoline-2 , -3-dione and the (E) isomer of indirubin (Z)-2,3’-Biindoline-2’-3-dione would be considered indigo derivatives even though they may differ in biological or physical properties.
• Some indigo derivatives are agonists of the aryl hydrocarbon receptor (AhR).
• AhR ligands include endogenous compounds as in Hubbard, T.D. etal and exogenous compounds like tapinarof (also known as benvitimod or 3,5-dihydroxy- 4-isopropylstilbene) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). It is believed that AhR activation results in downstream production of interleukin-22 which may mediate the activity of these compounds in the treatment of disease. Yet other compounds may induce the production of IL-22. In fact, stabilized delivery of IL-22 via linkage to polyethylene glycol (PEG) or the FC region of an antibody or other means may serve a similar biological effect in the treatment of disease.
• PEG polyethylene glycol
• FC region of an antibody or other means may serve a similar biological effect in the treatment of disease.
• the AhR agonist compound is a prodrug of indigo or of an indigo derivative that decomposes or is metabolized into indigo and/or an indigo derivative or other AhR agonist.
• prodrugs include mdican, indoxyl, leuco-indigo, and the like.
• the composition comprises indigo, an indigo derivative, a prodrug of indigo, a prodrug of an indigo derivative, and/or a combination of any of the foregoing.
• the composition comprises indigo, an indigo derivative, a prodrug of indigo, and/or a combination thereof, exclusive of prodrugs of an indigo derivative.
• the composition comprises an indigo derivative, a prodrug of indigo, a prodrug of an indigo derivative, and/or a combination thereof, exclusive of a prodrug of the indigo derivative indirubin.
• compositions containing indigo or a derivative, such as indirubin, that result in local but not systemic activation of the AhR are contemplated and described herein.
• Compositions that utilize solid amorphous dispersions of indirubin, described infra, have the advantage of being able to tune local and systemic bioavailability with a potent AhR agonist to maximize safety and efficacy in the treatment of human disease.
• Exemplary compositions are set forth in Example 1- 10, below.
• compositions were prepared using a synthetically manufactured indigo derivative, indirubin.
• a synthetically manufactured indigo derivative such as indirubin
• compositions of a solid amorphous dispersion of a synthetically manufactured indigo and/or an indigo derivative, such as indirubin, and a hydrophilic polymer carrier were prepared and analyzed.
• synthetic crystalline indirubin was prepared. It was dissolved a suitable solvent.
• FIG. 2A shows an image of one of the solid amorphous dispersions, where a reduced amount of crystalline mdirubin is apparent compared to films of FIGS. 1A-1B where synthetic indirubm is in crystalline form.
• FIG. 2B shows an image of another solid amorphous dispersion of indirubin and PVP, where no cry stalline indirubin is observed indicating indirubin was in dissolved in the solid PVP and in the form of a solid solution.
• Solid amorphous dispersions of synthetic indirubin were also prepared, as described in Example 12, from other exemplary' hydrophilic polymeric carriers - butylated methacrylate copolymer, methacrylic acid-ethyl acrylate copolymer, PVP, hydroxypropyl methylcellulose acetate succinate (HPMC-AS), hydroxypropylmethylcellulose phthalate (HPMCP), polyethylene oxide, polyvinyl acetate phthalate, poloxamer PI 88, and polyvinyl acetate and polyvinylcaprolactame-based graft copolymer (PVAc-PVCap- PEG).
• HPMC-AS hydroxypropyl methylcellulose acetate succinate
• HPMCP hydroxypropylmethylcellulose phthalate
• PVAc-PVCap- PEG polyvinyl acetate and polyvinylcaprolactame-based graft copolymer
• the solid amorphous dispersions were observed for color and presence of crystalline indirubin. It was observed that dispersions prepared with PVAc-PVCap- PEG and with polyvinylpyrrolidone-vinyl acetate copolymer (copovidone) were purple in color and had no visibly observable crystalline indirubin, indicating indirubin was in dissolved in the solid polymer in amorphous form and in the form of a solid solution.
• Example 13 describes additional studies where solid amorphous dispersions of synthetic indirubin were prepared from polyethylene oxide, HPMCP, HPMC-AS, butylated methacrylate copolymer, methacrylic acid-ethyl acrylate copolymer and PVAP using various solvents in the polymer solution.
• Tables 13-1 and 13-2 in Example 13 describe the visual inspection of the dispersions.
• substantially amorphous intends that the drug in the dispersion is at least about 50%, 60%, 70%, 75%, 80%, 85%, 90% or 95% amorphous, as determined, for example, by differential scanning calorimetry or x-ray diffraction, when compared to a crystalline indirubin reference sample.
• Dispersions of synthetic indirubin in PVP at polymer: drug ratio of 9: 1 with 10% indirubin (FIG. 3C) or 5% indirubin (FIG. 3D) show crystalline indirubin present in the dispersions, particularly at the higher weight percent of drug.
• Dispersions of synthetic indirubin in polyvinylpyrrolidone-vinyl acetate copolymer (copovidone) at polymer: drug ratio of 9: 1 with 10% indirubin (FIG. 3E) or 5% indirubin (FIG. 3F) yielded dispersions with essentially no crystalline drug.
• synthetic indirubin was in the form of a solid amorphous dispersion in the polyvinylpyrrolidone- vinyl acetate copolymer, at both 10% and 5% indirubin.
• Dispersions of synthetic indirubin in hydroxypropyl methylcellulose acetate succinate (HPMC-AS) at polymer: drug ratio of 9:1 with 10% indirubin (FIG. 3G) or 5% indirubin (FIG. 3H) yielded dispersions with essentially no crystalline drug. That is, synthetic indirubin was in the form of a solid amorphous dispersion in the HPMC-AS, at both 10% and 5% indirubin.
• FIGS. 3I-3J are diffractograms for dispersions of synthetic indirubin in
• hydroxypropylmethylcellulose phthalate HPMCP-HP55
• 10% indirubin FOG. 31
• 5% indirubin FOG. 3 J
• dispersions with the synthetic indirubin was in the form of a solid amorphous dispersion.
• PVAP polyvinyl acetate phthalate
• synthetic indirubin was substantially in amorphous form, particularly at the 5% drug load (FIG. 3L).
• Some of the solid dispersions displayed characteristic XRD peaks indicative of crystalline indirubin in suspension.
• Other dispersions displayed characteristic XRD peaks indicative of a reduced extent of crystalline indirubin in the solid amorphous dispersion (relative to the crystalline indirubin), with some indirubin in an amorphous form. See, for example, the povidone dispersions (FIGS. 3C-3D), the 10% indirubin copovidone dispersion (FIG. 3E), and the 10% PVAP dispersion (FIG. 3K).
• hydrophilic polymer carriers provided solid amorphous dispersions with indirubin substantially amorphous, as evidenced by a lack of XRD peaks indicative of crystalline indirubin, confirming that the indirubin was fully amorphous in suspension. See, for example, the dispersion with PVAc-PVCap-PEG (FIG. 3M), the 5% indirubin PVAP (FIG. 3L), HPMCP (FIG. 3J), HPMC-AS (FIGS 3G-3H) and the 5% indirubin in copovidone (FIG. 3F).
• the amount of indirubin in fasted-state simulated intestinal fluid was determined by HPLC for samples of the fluid taken.
• the mean amount of indirubin in solution at each time point was determined, and is shown in Table 1 in units of pg/L and in Table 2 as a percentage, referred to a %Q, of measured amount (mass) of indirubin in solution divided by the theoretical maximum amount (mass) of indirubin in solution.
• compositions including oral dosage forms and formulations, that release at least about 5%, 10%, 12%, 15%, 18%, 20%, 22% or 25% of the total amount of indirubin in the composition or in the dispersion.
• compositions, including oral dosage forms and formulations, that release at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% of the total amount of indirubin in the composition or in the dispersion are contemplated.
• polymer hydrophilic polymeric carrier
• indirubin synthetic or natural
• the solid dispersion comprises between about 5-80 wt% of the composition (e.g., dosage form or formulation), and in other embodiments, the solid dispersion comprises between about 6-80 wt%, 8-80 wt%, 10-80 wt%, 5-70 wt%, 8-70 wt%, 10-70 wt%, 5-60 wt%, 8-60 wt%, 10-60 wt%, 2-50 wt%, 3-50 wt%, 4-50 wt%, 5-50 wt%, 8-50 wt%, or 10- 50 wt% of the composition (e.g., dosage form or formulation).
• the composition e.g., dosage form or formulation
• Solid amorphous dispersions can be prepared by a variety of techniques, such as the solvent evaporation approach in the working examples to form fdms.
• Other approaches for removal of the solvent(s) include spray drying, freeze drying, drum drying, and precipitation.
• Still other approaches use no solvent, dissolving the material directly in a polymer via techniques such as hot melt extrusion.
• the synthetic indirubm of the compositions herein has a 14 C content of less than about 0.9 ppt 14C, less than about 0.8 ppt 14 C, less than about 0.7 ppt 14 C, less than about 0.6 ppt 14 C, less than about 0.5 ppt 14 C, less than about 0.4 ppt 14 C, less than about 0.3 ppt 14 C, less than about 0.2 ppt 14 C.
• the synthetic indirubin has a 14 C content of between about 0.001-1 ppt, 0.001-0.9 ppt, 0.01-1 ppt, 0.01-0.9 ppt, 0.05-1 ppt, 0.05-0.9 ppt, 0.08-1 ppt, 0.08-0.9 ppt, 0.09- 1 ppt, 0.1-1 ppt, 0.1-0.9 ppt.
• the synthetic indirubin has a fossil carbon content of greater than 10%, 20%, 30%, 40%, 50%, 60%, 70% or 80%.
• Example 17 compounds were tested for activation of the AhR receptor.
• the test articles were indirubin, indigo and Indigo naturalis. Each was incubated for 24 hours with reporter cells made from human Huh7 cells expressing human AhR and ARNT with luciferase expressed behind a genetic response element that responds to dimerized AhR/ ARNT. The results are shown in FIG. 4 as fold activation relative to a negative control just containing the solvent DMSO as a function of concentration of the test article.
• Indirubin is a potent activator of the AhR receptor.
• a dosage form comprising a dispersion of synthetic indirubin and a hydrophilic polymeric carrier is contemplated.
• the dosage form in an embodiment, is 20- fold, 30-fold, 40-fold or 50-fold more potent than Indigo naturalis (gram for gram) in its ability to activate the AhR in vivo.
• the dosage forms contemplated herein thus allow a dose of indirubin that is 10, 20, 30, 40 or 50 times less than the dose of Indigo naturalis.
• the dose of indirubin on the oral dosage forms described herein is between 0.1-30 mg, 0.1-25 mg, 0.2-30 mg, 0.2-25 mg, 0.3-30 mg, 0.3-25 mg, 0.3-20 mg, 0.5-30 mg, 0.5-25 mg, or 0.5-20 mg.
• a formulation or an oral dosage form comprised of a solid dispersion comprising amorphous synthetic indirubin in a hydrophilic polymer carrier, wherein the indirubin is in a substantially amorphous form in the dispersion; and one or more excipients in an amount greater than about 20 wt% of the formulation and blended with the solid dispersion to form a blend.
• the one or more excipients is/are present in the formulation in an amount greater than about 25 wt%, 30 wt%, 35 wt%, 40 wt%, 45 wt%, 50 wt%, 55 wt%, 60 wt%, 65 wt% or 70 wt%.
• the excipients may include binders, disintegrants, fillers, a flavoring agent, glidants, lubricants, pH modifiers, pigments, and/or surfactants.
• Binders contemplated for use include alginic acid, carbomer, carboxymethyl cellulose sodium, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxy ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, liquid glucose, maltodextrin, polymethacrylates, povidone, pregelatinized starch, sodium alginate, starch, and/or zein.
• Disintegrants include, but are not limited to, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone (crosslinked polyvinyl pyrrolidone), methyl cellulose, microcrystalline cellulose, powdered cellulose, sodium starch glycolate, sodium carboxymethyl cellulose, starch, pregelatinized starch, and sodium alginate.
• Fillers include sugars, such as lactose, mannitol, dextrose, sucrose, sorbitol, compressible sugar dextrates, dextran, dextrin, dextrose, maltodextrin, xylitol; celluloses such as microcrystalline cellulose, powdered cellulose; starches such as com starch, potato starch , pregelatinized starch; mineral salts such as calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, magnesium carbonate, magnesium oxide; and poloxamers such as polyethylene oxide.
• sugars such as lactose, mannitol, dextrose, sucrose, sorbitol, compressible sugar dextrates, dextran, dextrin, dextrose, maltodextrin, xylitol
• celluloses such as microcrystalline cellulose, powdered cellulose
• starches such as com starch, potato starch
• Glidants include, for example, silicon dioxide, talc, and cornstarch.
• Lubricants include calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate.
• pH modifiers include acids such as citric acid, acetic acid, ascorbic acid, lactic acid, tartaric acid, aspartic acid, succinic acid, phosphoric acid, and the like; bases such as sodium acetate, potassium acetate, calcium oxide, magnesium oxide, trisodium phosphate, sodium hydroxide, calcium hydroxide, aluminum hydroxide, and the like; and buffers generally comprising mixtures of acids and the salts of said acids.
• the one or more excipients are present in the dosage form or formulation at between 20-90 wt%, 20-85 wt%, 20-80 wt%, 20-75 wt%, 20-70 wt%, 20-65 wt%, 20-60 wt%, 20-55 wt%, 20-50 wt%, 20-45 wt%, 20-40 wt%, 30-90 wt%, 30-85 wt%, 30-80 wt%, 30-75 wt%, 30- 70 wt%, 30-65 wt%, 30-60 wt%, 30-55 wt%, 30-50 wt%, 30-45 wt%, 30-40 wt%, 40-90 wt%, 40-85 wt%, 40-80 wt%, 40-75 wt%, 40-70 wt%, 40-65 wt%, 40-60 wt%, 40-55 wt% or 40-50 wt%.
• the dosage form or the formulation achieves one or more of (i) the release of substantially all of the indirubin from the dosage form in the small intestine, large intestine and/or colon; and (ii) the release of substantially all indirubin from the dosage form within about 60 minutes when at a pH above 5; (lii) the release of substantially all of the indirubin from the dosage form over a period of about 8 hours when at a pH of above 5.
• one or more of (i), (ii) or (lii) is achieved without use of an enteric polymer coating on the outside of the dosage form.
• one or more of (i), (ii) or (iii) is achieved with the use of an enteric polymer coating on the outside of the dosage form.
• the dispersion in some embodiments, has an mdirubin solubility in simulated intestinal fluid greater than a dispersion containing the same amount of indirubin in the form of crystalline indirubin, Indigo naturalis or a 1:9 povidonehndirubin solid dispersion in simulated intestinal fluid, at the same temperature.
• the indirubin remains in a substantially amorphous form the dispersion for at least about 6 months when stored at 25°C.
• the dispersion does not contain indigo, and/or wherein the dosage form does not contain indigo.
• the hydrophilic carrier is not hypromellose acetate succinate and/or wherein the solid dispersion is not produced via precipitation from dimethylacetamide.
• the polymeric hydrophilic carrier is not povidone.
• the dosage form or the formulation when administered it provides a therapeutic effect with respect to treating ulcerative colitis that is equal or superior to the therapeutic effect provided by an oral composition of Indigo naturalis containing an equivalent amount of indirubin.
• the dosage form or formulation when administered it provides a reduction in observed side effects compared to the side effects obser ed following administration of Indigo naturalis.
• a composition comprised of a compound selected from indigo, indirubin, isatin, and combinations thereof, and a pharmaceutically acceptable carrier is provided, wherein the composition provides a therapeutic effect with respect to treating UC that is substantially the same as provided by a composition of Indigo naturalis.
• the composition may provide a superior effect or superior therapeutic effect with respect to treating UC as compared to the therapeutic effect provided by a composition of Indigo naturalis.
• the composition may provide a reduction in observed side effects compared to the side effects observed following administration of Indigo naturalis.
• Indigo naturalis examples of side effects observed upon oral administration of Indigo naturalis can be, for example, pulmonary arterial hypertension, liver dysfunction, headache, nausea, diarrhea, vomiting, intussusception, ischemic colitis.
• the composition provides a superior therapeutic effect with respect to treating UC as compared to the therapeutic effect provided by a composition of the carrier and indigo, mdirubin, or isatin individually.
• the effects of the composition when compared to Indigo naturalis are ascertained when the compositions are administered via the same route of administration and/or at essentially the same dose of at least one of the active compounds, e.g., indigo or indirubin or another indigo derivative.
• the compound or compounds in the composition e.g., indigo, indirubin, and/or isatin
• the compound or compounds in the composition is/are synthetically produced or synthetically synthesized, in one embodiment.
• the compound or compounds in the composition e.g., indigo, indirubin, and/or isatin
• the compound or compounds, whether synthetically produced or obtained from a processing technique of a plant extract is/are combined with a pharmaceutically acceptable carrier to provide a composition for administration to a subject.
• a composition that is not Indigo naturalis and that is comprised of indigo and/or an indigo derivative is contemplated.
• indigo and/or the indigo derivative may be synthetically produced, extracted and/or isolated from plants, or made via fermentation or bioreactor. Chemical synthesis and biosynthesis of indigo and/or indigo derivatives is described, for example, in Ensley et al., Science, 167 (1983)). Processing of plants to enrich the extract in one or more of indigo and/or an indigo derivative is another approach to production of a composition, that is not Indigo naturalis, and that comprised of indigo and/or an indigo derivative.
• compositions comprising a single compound, in some embodiments, comprise between about 0.001-15 wt%, 0.001-10 wt%, 0.001-5 wt%, 0.01-15 wt%, 0.01-10 wt%, 0.01-5 wt%, 0.05-15 wt%, 0.05-10 wt%, 0.05-5 wt%, 0.1-15 wt%, 0.1-10 wt%, 0.1-5 wt%, 0.2-15 wt%, 0.2-10 wt%, 0.2-5 wt%, 0.3-15 wt%, 0.3-10 wt%, 0.3-5 wt%, 0.4-15 wt%, 0.4-10 wt%, 0.4-5 wt%, 0.5-15 wt%, 0.5-10 wt%, 0.5-5 wt%, 0.6-15 wt%, 0.6-10 wt%, 0.6-5 wt%, 0.7-15 wt%, 0.7-10 wt%, 0.4-5 w
• the composition comprises at least two compounds selected from indigo, indirubin, and/or isatin.
• the compounds are present, in some embodiments, in one of the following weight percentages based on the weight of the active agent (therapeutic) compounds in the composition (e.g., not based on total weight of the composition):
• compositions comprised of indigo, indirubin, and/or isatin at least one of the compounds is present in the composition in an amount at least 10%, 15%, 20%, or 25% greater by weight than the amount by weight in Indigo naturalis or in an amount at least 10%, 15%, 20%, or 25% greater relative to the amount present m Indigo naturalis.
• compositions comprised of indigo, indirubin, and/or isatin at least one of the compounds is present in the composition at least one of the compounds is present in the composition in an amount at least 10%, 15%, 20%, or 25% less by weight than the amount by weight in Indigo naturalis or in an amount at least about 10%, 15%, 20%, or 25% less relative to the amount present in Indigo naturalis.
• the active agent in the compositions comprises, consists essentially of, or consists of indirubin and indigo; or indirubin and isatin; or indigo and isatin.
• indirubin and indigo When indirubin and indigo are present in the composition, they may be in a ratio of indirubin to indigo from about 1:100 to 10:1, 1:30 to 30:1, 1:25 to 25:1, 1:20 to 20:1, 1:15 to 15:1, 1:10 to 10:1.
• indirubin and isatin are present in the composition, they may be in a ratio of indirubin to isatin from about 1:30 to 30:1, 1:25 to 25:1, 1:20 to 20:1, 1:15 to 15:1, 1:10 to 10:1.
• indigo and isatin When indigo and isatin are present in the composition, they may be in a ratio of indigo to isatin from about 1:30 to 30:1, 1:25 to 25:1, 1:20 to 20:1,
• the various combinations of active agents can be in a ratio of the first active agent to the second active agent from about from about 100:1 to 1:10, 10:1 to 50:1, 15:1 to 50:1, 20:1 to 50:1, 25:1 to 50:1, 15:1 to 45:1, 20:1 to 45:1, 25:1 to 45:1, 30:1 to 45:1, 20:1 to 30:1, 20:1 to 35:1, 20:1 to 40:1, or 30:1 to 35:1.
• the ratio of first active agent to the second active agent is about 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1,
• the composition comprises at least two compounds selected from indigo, indirubin, and isatin, and a pharmaceutically acceptable carrier, wherein the composition is not Indigo naturalis.
• the weight percent of the first active agent based on the total weight of the active agents in the composition, is between about 25-99 wt%, 25-98 wt%, 25-96 wt%, 25-95 wt%, 25-90 wt%, 25-85 wt%, 25-75 wt%, 25-70 wt%, 25-65 wt%, 25-60 wt%, 25-55 wt%, 25-50 wt%, 25-45 wt%, 25-40 wt%, or 25-35 wt%.
• the weight percent of the second active agent is between about 25-99 wt%, 25-98 wt%, 25-96 wt%, 25-95 wt%, 25-90 wt%, 25-85 wt%, 25-75 wt%, 25-70 wt%, 25-65 wt%, 25-60 wt%, 25-55 wt%, 25-50 wt%, 25-45 wt%, 25-40 wt%, or 25-35 wt%.
• indigo and indigo derivatives may be substituted with boron, H3 or radioactive moieties.
• indigo and/or the indigo derivative can be in the form of a solid.
• This solid may be highly crystalline or bound to inorganic and organic material that has crystalized out of solution or been evaporated down into a solid.
• This material may be processed into a powder.
• the powder may have a uniform or widely distributed average particle size.
• the particle size may be on the nanometer scale, the micrometer scale or larger. Powders of uniform particle sizes may have different solubility or bioavailability based on their crystalline structure, surface area, co-crystals or isoform. This relative bioavailability or lack thereof may make these agents more effective, less effective or safer or less safe in treated patients with a disease.
• larger particle sizes or reduced surface area may be less soluble and, therefore, less bioavailable resulting in less systemic exposure and therefore better safety while maintain local activity and efficacy.
• treating patients with formulations made from these particles may result in reduced liver toxicity, reduced serotonin levels or reduced pressure in the lungs or a reduced chance of developing pulmonary arterial hypertension compared to more bioavailable particles such as those that may be found in Indigo naturalis.
• the solid particles of indigo and/or indigo derivatives can have average particle sizes of less than about 5000 nm, less than 3000 nm, less than 2000 nm or less than 1500 nm. In other embodiments, the solid particles of indigo and/or indigo derivatives can have average particle sizes of equal to or greater than about 1500 nm, 2000 nm, 2500 nm, 3000 nm or 5000 nm. In some embodiments, more than about 60%, 70%, 75%, 80% 85% or 90% of the particles are larger than about 1500 nm, 2000 nm, 2500 nm, 3000 nm or 5000 nm.
• more than about 60%, 70%, 75%, 80% 85% or 90% of the particles are smaller than about 1500 nm, 2000 nm, 2500 nm, 3000 nm or 5000 nm.
• the particles can contain optionally include a surface stabilizer, or may exclude a surface stabilizer.
• the indigo and/or indigo derivatives can be bound to or mixed with particles that contain calcium carbonate, cellulose, organic resins, inorganic resins, clay or zeolites. In some embodiments, the indigo and indigo derivatives can be free from calcium carbonate or cellulose.
• the solid powder contains multiple active agents, such as indigo and/or one or more indigo derivatives, in the same particle or in the same population of particles.
• the solid powder contains a mixture of distinct particles each comprising an active agent of indigo or a particular indigo derivative.
• the particles are at least about 95%. 96%, 97%, 98% or 99% pure or are over 99.9% pure.
• the solid particles can each have the same average particle size or can have different average particles sizes.
• the solid particles may have the same solubility in a selected solvent (e.g., water or ethanol) or may have the same bioavailability.
• the composition differs in solubility or bioavailability from Indigo naturalis that contains the same about of a given active agent (e.g., indigo or an indigo derivative).
• a given active agent e.g., indigo or an indigo derivative
• This difference in solubility may be seen in solvents including water, low pH water, or certain formulation solvents, such as ethanol, n-methyl pyrrolidone, polyethylene glycol, or dimethylsulfoxide.
• This difference in solubility or bioavailability may be to the particle surface area, particle size, particle shape, contaminants, purity and/or hydrophobicity of the particles or excipients included in a given formulation.
• the indigo and indigo derivatives may be free from or reduced substantially of impurity found in Indigo naturalis, in some embodiments.
• the impurity may be an allergen or toxin.
• the impurity may be indigo, indirubin, isatin, indospicine or 3-nitropropionate.
• the impurity may be inorganic, or may be a heavy metal, such as arsenic, cadmium, lead or mercury.
• the impurity may also be a pesticide, silicon dioxide, limestone, cellulose, water, or calcium carbonate.
• the indio and/or indigo derivative is substantially free of one or more of such impurities.
• the indigo and/or indigo derivatives may have less bioburden per gram than Indigo naturalis, in some embodiments.
• the indigo and/or indigo derivatives may have a reduced bacterial count, reduced yeast count, reduced mold count, reduced e-coli count and/or reduced salmonella count than a preparation of Indigo naturalis.
• the indigo and/or indigo derivatives may be more resistant to the growth of microorganisms.
• the indigo and/or indigo derivatives may have less than about 15,000, 25,000, 35,000 or 50,000 colony forming units per gram.
• the indigo and/or indigo derivatives may be sterile.
• the indigo and/or indigo derivatives may include a preservative that inhibits bacterial and/or microbe growth over time.
• the indigo and/or indigo derivatives may differ in color than Indigo naturalis and may be more dark blue, light blue or blackish.
• the indigo and/or indigo derivatives may be purplish, reddish, orangish, pinkish, or brownish.
• the indigo be lighter in color, white or clear.
• the indigo and/or indigo derivatives may be reduced into their reduced forms changing their color or rendering them less colored or even colorless or white.
• the indigo and/or indigo derivatives may have particle sizes in the nanometer range or may have a unique structure that alters their color compared to what is found in Indigo naturahs or what has been purified from synthetic preparations.
• compositions containing Indigo naturahs may change the color of the stool, urine or other bodily fluids or surfaces. This may not be desirable to a patient being treated. Additional dyes or colorants may be added to a formulation containing Indigo naturahs or Indigo and/or indigo derivatives in order to normalize the color of the stool urine or bodily fluids. In one example, a reddish dye such beetroot extract or FD&C red no. 3 may be added to Indigo naturahs in order to keep stools brown in color rather than turning blueish or greenish.
• Indigo and/or indigo derivatives in one embodiment, have a half maximal effective concentration (EC50) of less than about 10 nM, 8 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.5 nM, 0.2 nM or 0.1 nM for the human aryl hydrocarbon receptor as measured via a yeast aryl hydrocarbon receptor using human aryl hydrocarbon receptor and aryl hydrocarbon nuclear transporter proteins with a readout in beta-galactosidase activity or luciferase activity.
• EC50 half maximal effective concentration
• the half maximal effective concentration (EC50) of two of indigo and/or indigo derivatives on the activation of the human aryl hydrocarbon receptor would be reduced in an addihve manner or in a synergistic mechanism to be a greater reduction than what is anticipated from the additive response of the single indigo and/or indigo derivatives.
• Indigo and indigo derivatives are exemplary kinase and transcription factor inhibitors.
• the compositions mentioned above can comprise agents that also inhibit a kinase or transcription factor.
• These kinase or transcription factors may be in a post-translationally modified or unmodified form including but not limited to being in a phosphorylated or unphosphorylated form. They may be free or associate with other enzymes or cofactors as part of a complex.
• the agents can be an inhibitor of a signal transducer and activator of transcriptions (STAT) such as STAT3, a Janus kinase (JAK) such as JAK2, a mitogen-activated protein kinase (MAPK) which includes extracellular signal-regulated kinase (ERK) such as ERK2, a tyrosine-protein kinase such as C-src ty rosine kinase, a casein kinase such as casein kinase 1, a cyclin-dependent kinase (CDK) such as CDK1, CDK2 or CDK5 or a glycogen synthase kinase (GSK) such as GSK3B at a half maximal effective concentration
• STAT signal transducer and activator of transcriptions
• JAK2 Janus kinase
• MAPK mitogen-activated protein kinase
• ERK extracellular signal-regulated kinase
• Indigo and/or indigo derivatives may also be cytotoxic to fast dividing cells.
• the compositions mentioned herein can comprise agents that are cytotoxic to fast diving cell such as CD4+ T-cells at a half maximal effective concentration (IC50) of less than about 100 mM,
• the compositions also comprise a carrier or a pharmaceutically acceptable vehicle or excipient, to ease administration to a person in need.
• the composition is formulated for localized delivery.
• Localized delivery includes local delivery to a tissue, such as skin (e.g. via topical delivery), to an organ, or to the gastro-intestinal tract (e.g., via oral delivery, rectal delivery).
• localized delivery is to intact or disrupted mucosal tissue.
• localized delivery is to the oral mucosa.
• the localized delivery is to the small intestine, the esophagus, stomach, oral mucosa, rectum or to the colon.
• the carrier will vary depending on the desired composition, which can take a number of different forms, including, for example, a tablet, a capsule, a gel cap, an enteric-coated tablet, an enteric-coated tablet capsule, an enteric-coated gel cap, a collection of microspheres, a collection of nanoparticles, a suspension, a powder for suspension, an orally-disintegrating tablet, a buccal tablet, an orally- dissolving film, a lozenge, a suppository, foam, an enema, an ointment, a cream, a lotion, a gel, and the like.
• suitable formulations is found, for example, in
• the composition comprises one or more carriers to achieve colonic delivery of the compound or compounds.
• a composition designed for colonic release may employ one of the following features to target release of the compounds predominantly in the colon relative to other portions of the gastrointestinal tract: (1) the generally increasing pH profile of the lumenal contents up to the ileocecal junction; (2) the relatively constant small intestinal transit time of an orally administered composition; and (3) the presence of endogenous bacteria in the colon (M. Ashford et ak, J. Drug Targeting, 2:241-258 (1994)).
• Oral dosage forms formulated for localized delivery in the colon comprise a carrier in the form of a pH-sensitive polymer.
• the pH varies along the length of the gastrointestinal tract, from a pH of 1 to 2 in the stomach and to a pH of around 7.5 in the distal small intestine. The pH then declines from the end of the small intestine to the colon and gradually increases once again in the colon.
• a composition comprising a carrier that is pH-sensitive, for example, a pH-sensitive coating membrane or a pH sensitive polymeric hydrophilic carrier, can achieve release of the compounds in the colon.
• a pH-sensitive polymer that breaks down at a basic pH and remains intact at acidic pHs protects the compound from the acidic pH of the stomach and proximal small intestine. These polymers then break down in the more basic pH of the terminal ileum, thus providing a targeted drug delivery to the colon.
• Polymers based on poly-methacrylate such as Eudragit® L and Eudragit® S have frequently been used for this purpose, and each one has its own unique pH value at which it dissolves. These two polymers have been mixed in different ratios to form a coating with an optimized dissolution rate. Additionally, coatings with these polymers are designed to be relatively thick to prolong their dissolution, and provide a controlled or an extended drug release.
• the polymeric hydrophilic carrier is a pH sensitive polymer that dissolves or becomes soluble at a pH between 4.5-7.5 in the intestinal tract or in simulated gastric fluid at a temperature of 25°C or 30°C or 35°C.
• the polymeric hydrophilic carrier dissolves or becomes soluble at a pH between 4.5-7.5 and is insoluble at pH 1.5-3.5 in the intestinal tract or in simulated gastric fluid at a temperature of 25°C or 30°C or 35°C.
• the composition comprises a carrier that achieves a delayed release of the indigo compound(s) and/or indigo derivative compound(s) for a period of time approximately corresponding to the residence time in the small intestine.
• An exemplary composition is one having a single enteric polymer layer or multiple enteric polymer coating layers.
• Compositions with multiple enteric polymer coating layers may comprise an outermost layer consists of an enteric polymer that begins to dissolve at pH 6.8 to 7.2 and an inner coating layer of an enteric polymer that begin to dissolve at pH 5.0 to 6.3 in an amount such complete dissolution substantially occurs within the proximal colon.
• the function of the outermost coating layer is to prevent release of the therapeutic agent as the dosage form transits the gastrointestinal tract to the distal small intestine
• the function of the inner coating lay ers is to further delay release of the therapeutic agent until the dosage form has reached the proximal colon. Examples of such compositions are detailed in EP0825854.
• Exemplary pH sensitive polymers include cellulose acetate phthalate; cellulose acetate trimelliate; hydroxypropyl methylcellulose phthalate; hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate; hypromellose acetate succinate; hypromellose phthalate; poly(methacrylic acid, methyl methacrylate) 1: 1; poly(methacrylic acid, ethyl acrylate) 1 :1, poly(methacrylic acid, methyl methacrylate) 1:2, and a mixture of
• pH sensitive polymers may be made in different grades which allow for dissolution at various pHs.
• HPMC is available in different grades including HPMC AS F912, HPMC AS 716 and HPMC AS 126 that vary in their relative amount of monisuccinic acid and acetic acid esters giving them unique stability and dissolution properties at various pHs.
• these pH sensitive polymers may also be incorporated into the dosage forms themselves.
• the polymer can be used to dissolve the AhR agonist and may result in the form of a solid suspension.
• the AhR agonist may be indirubin.
• the AhR agonist may be a partially or fully amorphous solid suspension when dissolved within one of these pH sensitive polymers. In one example, this will protect the AhR agonist from both being degraded by the low pH of the stomach and may limit systemic adsorption.
• the drug product When in the form of a solid dispersion made of a hydrophilic polymer, including a pH sensitive polymer, the drug product offers improved better dispersion and dissolution when dosed orally than a dosage from that is merely coated with the same hydrophilic polymer or pH sensitive polymer.
• These solid suspensions dissolved in a hydrophilic polymer or a pH sensitive polymer may be in the form of a tablet or capsule which is subsequently coated with a single enteric polymer layer or multiple enteric polymer coating layers that may be of the same of different compositions as the polymer used in the solid suspension.
• Colonic targeted delivery can also be achieved by relying on the aerobic and anaerobic microorganisms like Escherichia and Clostridium species, respectively, resident in the colon. These bacteria contain several hydrolytic and reductive metabolizing enzymes that can catalyze a range of reactions. Polysaccharides such as chitosan, guar gum, pectin, etc. , can be employed as release rate-controlling components in colon-targeted dosage forms as these polysaccharides are resistant to gastric and intestinal enzymes, but are metabolized by anaerobic bacteria in the colon.
• acetyl derivatives of guar gum, azo-aromatic polymers are examples of polymers susceptible to degradation by colonic enzymes. These polymers can be used to coat the indigo and/or indigo derivative to protect them from degradation by peptidases in the stomach and small intestine while still permitting drug release in the colon.
• Another approach towards colon-targeted drug delivery includes embedding the drug in polymer matrices to trap it and release it in the colon. These matrices can be pH-sensitive or biodegradable. Timed-released formulations are based on the drug being released in the colon after a specified amount of time. This approach is dependent on the transit time through the small intestine, which is and known to vary between 3 and 4 hours. A combination of pH- sensitive polymers and a timed-release approach to achieve colon-specific delivery may also be used, such as enclosing a core of the indigo or indigo derivate compound(s) in polymeric layers of a hydrophilic layer sandwiched between two pH-sensitive layers.
• Bioadhesive compositions are another approach for localized delivery.
• a bioadhesive composition allows a formulation to remain in contact within an organ, in this case the colon, for a long period of time.
• Some of the polymers which have been explored as bioadhesive components for these systems include polycarbophils, polyurethanes, and polyethylene oxide.
• Multiparticulate systems have a smaller particle size compared to single-unit systems, and studies have shown that they can reach the colon more quickly since they pass through the GI tract more easily.
• Microspheres are one example of a multiparticulate system that can be loaded with a drug for colonic delivery .
• An example is a core of the indigo or indigo derivate compound(s) mixed with cross-linked chitosanor a polysaccharide pectin to form microspheres that are then coated with a pH-sensitive polymer available under the tradename EUDRAGIT®.
• Polysaccharide-based carriers are another option to achieve colon-specific delivery of the indigo or indigo derivate compound(s).
• examples include xanthan gum and guar gum formulated with the compound(s) to form solid matrix tablets.
• polysaccharides as the carrier is also effective for achieving colon-specific delivery .
• Cellulose derivatives may be used alone or in combination with a polysaccharide, as cellulose is not absorbed systemically when administered orally.
• Non-enteric cellulose esters such as cellulose acetate are insoluble in water and their solubility is independent of pH. These can be used in insoluble, permeable coatings.
• Enteric cellulose esters such as cellulose acetate phthalate (CAP) and hydroxypropyl methylcellulose phthalate (HPMCP) have solubilities which are pH- dependent. They are insoluble in highly acidic conditions, but when the pH reaches a certain range they dissolve. The pH at which the polymer dissolves varies depending on the extent of esterification.
• carbohydrate mixtures include pectin-HPMC, chitosan- HPMC, chitosan-pectin, guar gum-chitosan, and dextran-chitosan.
• Additional embodiments may include single carriers or a combination of earners both to prevent the indigo compound(s) and/or indigo derivative compound(s) from being released in the stomach and to maximize or minimize absorption, retention or dispersion or solubility across or through certain anatomical regions.
• Examples include moieties that become adhesive to areas of inflammation, specific cell types or mucosa, moieties that prolong the
• moieties that increase local or systemic penetration into or through the lumen of the small intestine or colon moieties that enhance or prevent the disposition of the active agents and moieties that increase the solubility when exposed to changes in the colon.
• Some of the moieties may be activated by pH, time or enzymatic activity specific to the small intestine or colon.
• carriers to target inflammatory lesions may include hydrogels, polymers or fibers made of ascorbyl palmitate.
• Some embodiments may include carriers to increase solubility or stability.
• exemplary carriers include surfactants such as tween-80, and complexing-agents such as cyclodextrins and co-solvents such as pentanol.
• compositions described herein may also contain relatively small amounts, e.g., less than about 10% (w/w) of one or more auxiliary excipients including but not limited to pH modifying agents, preservatives, thickening agents, gel-forming agents, emulsifying agents, antioxidants, scent agents, and the like.
• auxiliary excipients including but not limited to pH modifying agents, preservatives, thickening agents, gel-forming agents, emulsifying agents, antioxidants, scent agents, and the like.
• auxiliary excipients including but not limited to pH modifying agents, preservatives, thickening agents, gel-forming agents, emulsifying agents, antioxidants, scent agents, and the like.
• Compounds suitable for incorporation may be found, e.g., in R.C. Rowe, et ah, Handbook of Pharmaceutical Excipients (4th Ed.), Pharmaceutical Press, London, 2003.
• compositions described herein may also comprise an agent to alter viscosity or to gel the composition.
• examples include cellulose ethers such as hydroxypropyl cellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose , and the like; vinyl alcohols; vinyl pyrrolidones; natural gums such as karaya gum, locust bean gum, guar gum, gelan gum, xanthan gum, gum arabic, tragacanth gum, carrageenan, pectin, agar, alginic acid, sodium alginate and the like, and methacrylates such as those available under the tradename Eudragit® from Rohm Pharma.
• gelling agents include polyoxyethylene— polyoxypropylene copolymers (poloxamers) such as those available under the tradename“Lutrol®”, and the like.
• Other gelling agents are those absent free carboxyl groups such as, for instance, hydroxypropylcellulose,
• hydroxypropylmethylcellulose hydroxyethylcellulose, methylcellulose, organo/cold water soluble cellulose, hydroxy ethylmethylcellulose, ethylcellulose, ethyl(hydroxyethyl)cellulose.
• compositions described herein may also contain an antioxidant.
• the amount of antioxidant if present, will typically range from about 0.005% to about 3.0% by weight of the composition. Illustrative ranges include from about 0.01% to about 2.5% by weight antioxidant, from about 0.05% to about 2% by weight antioxidant, and from about 0.1% to about 1.5% by weight anti-oxidant.
• Suitable antioxidants include, for example, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), tertiary butyl hydroquinone, propyl gallate, a-tocopherol, sodium metabisulfite, and the like.
• compositions described herein may further contain one or more preservatives in an amount typically ranging from about 0.01% to about 2.0% by weight of the composition.
• preservatives include, for example, phenoxyethanol, methyl paraben, propyl paraben, butyl paraben, benzyl alcohol, and the like.
• compositions described above may be prepared by combining together the components at a temperature and for a time sufficient to provide a pharmaceutically effective and elegant composition.
• combining together means that all of the components of the compositions may be combined and mixed together at about the same time.
• combining together also means that the various components may be combined in one or more sequences to provide the desired product.
• the formulation can be prepared on a weight/weight (w/w) or a weight/volume (w/v) basis depending upon the form of the final dosage form.
• compositions may be packaged for use in a medical setting or for retail distribution directly to the consumer (i.e., an article of manufacture or kit). Such articles will be labeled and packaged in a manner advising the patient how to use the product for therapy. Such instructions will include the duration of treatment, dosing schedule, precautions, dietary recommendations or foods or medications to avoid etc. These instructions may be in the form of pictures, written instructions, or a combination thereof. They may be printed on the side of the packaging, be an insert, or any other form of communication appropriate for the retail market.
• compositions may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy.
• the composition can be placed in an appropriate container, such as a tamper-proof bottle, a foil- lined blister pack, a time-released jar, or a device for dispensing unit dosages of the formulation, such as a bottle or dropper that dispenses a controlled pre-determined dosage of the composition.
• the methods and compositions can optionally be used in combination with one or more other therapies, such as one or more therapeutic agents, surgery and/or radiation.
• the methods and compositions provided herein are used in combination with one or more therapeutic agents.
• compositions e.g., the dosage form or formulations described herein are contemplated.
• methods for treating are related to subject with gastro-intestinal inflammatory diseases, such as ulcerative colitis or Crohn’s disease.
• a method for treating ulcerative colitis comprises administering to a subject a therapeutically effective amount of a composition comprising indigo, indirubin, isatin, or a combination thereof, wherein the composition is not Indigo naturalis, whereby the administering treats UC in the subject.
• the subject with UC is refractory or intolerant to treatment with a known therapy, including but not limited to, 5-aminosalicylic acid, a prodrug of 5- aminosalicyline acid, a steroid, an anti-TNF-alpha antibody, a Janus kinase inhibitor (e.g., peficitinib, tofacitinib), an integrin receptor antagonist, such as vedolizumab (an alpha-4B7 integrin antagonist), a sphingosine-1 -phosphate receptor modulator, such as ozanimod, and/or any other known drug therapy for UC (e.g., Ko, C. et al., Gastroenterology, 156(3):748-764 (2019)).
• a known therapy including but not limited to, 5-aminosalicylic acid, a prodrug of 5- aminosalicyline acid, a steroid, an anti-TNF-alpha antibody, a Janus kinase inhibitor
• the subject with UC has previously been treated with 5- aminosalicylic acid or a prodrug of 5-aminosalicyline acid, such as sulfasalazine.
• the subject has mild to moderate UC. In another embodiment, the subject has moderate to severe UC. Mild to moderate UC is defined by the American Gastroenterological Association as fewer than 4-6 bowel movements per day, mild or moderate rectal bleeding, absence of constitutional symptoms, low overall inflammatory burden, and absence of features suggestive of high inflammatory activity (Ko, C. et al, Gastroenterology, 156(3):748-764 (2019)).
• a method for treating ulcerative colitis (UC), for treating inflammatory bowel disease, for preventing recurrence of UC, for treating UC in a subject previously treated with 5-aminosalicylic acid or a prodrug of 5-aminosalicyline acid, for preventing recurrence of UC, for treating UC in a subject refractory or intolerant to treatment with a known therapy are each contemplated, and comprise administering the a subject in need a dosage form or formulation (a composition) as described herein, to provide a therapeutically effective amount of the aryl hydrocarbon receptor agonist, such as indirubin.
• a method for treating inflammatory bowel disease or for treating a gastro-intestinal inflammatory disease in a subject comprises administering to a subject a therapeutically effective amount of a composition comprising indigo, indirubin, isatin, or a combination thereof, wherein the composition is not Indigo naturalis, whereby the administering treats the inflammatory bowel disease in the subject.
• the inflammatory bowel disease is not Crohn’s disease.
• the amount of drug compound needed to achieve and or maintain a clinical response after 8 weeks of treatment is less than 0.5 grams per day of Indigo naturalis.
• treating is for a duration of longer than about 8 weeks or about 10 weeks to achieve and/or maintain a clinical response and/or clinical remission.
• treating or administering of the indigo and/or indigo derivative is for maintenance of clinical remission.
• a ratio of indigo to indirubin that is greater than about 3-fold is administered in the composition to achieve and/or maintain clinical response after about 8 weeks of treatment.
• a dose of greater than about 6 mg of indigo is administered to achieve clinical response and/or maintain clinical remission.
• a dose of greater than about 2 mg of indigo is administered daily for 8 weeks to achieve clinical response and/or maintain clinical remission.
• a dose of greater than about 2 mg of indirubin is administered daily for 8 weeks to achieve clinical response and/or maintain clinical remission.
• a dose of less than about 0.66 mg of indirubin is administered daily for 8 weeks to achieve clinical response and/or maintain clinical remission.
• indigo is present in the composition at a concentration greater than 0.3 wt% and/or indirubin is present in the composition at a concentration greater than 0.1 wt% to achieve and/or maintain a clinical response.
• the dosage form or formulation yields a non-therapeutic blood level of indirubin. In one embodiment, the dosage form or formulation yields a systemic blood level of less than about 1 nM of the compound.
• the clinical response is a single measurement or, in other embodiments, is a compilation of measurements, at or before or after 8 weeks of treatment, where the measurement(s) includes but is/are not limited to: clinical response on the Mayo score defined as a decrease from baseline in Mayo score of >3 points and >30%, with an accompanying decrease in the subscore for rectal bleeding of >1 point or absolute subscore for rectal bleeding of 0 or 1, clinical remission defined as a Mayo score ⁇ 2 with no individual subscore >1) and rectal bleeding subscore of 0, an improvement in the endoscopic index of seventy, a reduction in calprotectin in the stool to levels below lOOug/g, improvement in quality of life as measured via the short irritable bowel disease questionnaire, a reduction in inflammator immune cells in the colonic mucosa such as CD8+ T-cells, Thl7 cells or neutrophils, a reduction in systemic or colonic inflammatory cytokines such as TNFa or
• compositions comprising indigo and/or an indigo derivative that does not include one or more of indole, indole-3- aldehyde, tryptanthrin, botulin, beta-sitosterol, daucosterol, indicant, and anthranilic acid to achieve and/or maintain a clinical response.
• a companion diagnostic together with a composition comprising indigo and/or an indigo derivative, wherein the diagnostic provides an indicator useful to titrate dose of the composition to achieve a non- therapeutic blood level.
• composition comprising solely the E-stereoisomer of indirubin to achieve and/or maintain a clinical response.
• composition comprising solely the Z-stereoisomer of indirubin to achieve and/or maintain a clinical response.
• composition a mixture of the E-stereoisomer and Z-stereoisomer of indirubin.
• a method for preventing recurrence of UC comprises administering to a subject a therapeutically effective amount of a composition comprising indigo, indirubin, isatin, or a combination thereof, wherein the composition is not Indigo naturalis, whereby the administering prevents recurrence of UC in the subject.
• Ulcerative colitis is a chronic, relapsing and remitting inflammatory bowel disease of unknown etiology that affects the colon and rectum in a circumferential and continuous manner. Depending on the extent of involvement, UC is classified as proctitis, proctosigmoiditis, left-sided colitis or pancolitis. Common symptoms include bloody diarrhea, fecal urgency and abdominal pain.
• UC is often treated with mesalamine, glucocorticoids, azathioprine, anti-tumor necrosis factor (TNF) agents (infliximab and adalimumab), 5- aminosalicylate drugs (e.g., Delzicol, Asacol, Pentasa, etc.), corticosteroids, Janus kinase (JAK) inhibitors, such as tofacitinib, peficitinib and filgotinib, other immunosuppressive agents and other biologic agents.
• mesalamine glucocorticoids
• azathioprine anti-tumor necrosis factor (TNF) agents
• TNF anti-tumor necrosis factor
• TNF anti-tumor necrosis factor
• JK Janus kinase
• Inflammation in UC subjects is typically limited to the mucosa and extends from the rectum proximally.
• Crohn’s disease another inflammatory bowel disease, is characterized by transmural inflammation in any part of the gastrointestinal tract.
• the compositions described herein are contemplated for treating an inflammatory bowel disease.
• the compositions described herein are contemplated for treating an inflammatory bowel disease that is not Crohn’s disease.
• compositions described herein are contemplated for treating other inflammatory conditions, such as hidradenitis suppurativa (HS).
• HS is a chronic inflammatory skin condition involving the follicular portion of folliculopilosebaceous units of apocrine gland-bearing skin. Patients can present with recurrent nodules, sinus tracts formation, abscesses, and/or scarring. The disease can manifest anywhere there are apocrine glands or hair follicles including the underarm, groin, buttocks and under the breasts.
• the composition is a topical composition that is applied to the skin, in various embodiments, at least once daily, or at least two, three or four times daily. In one embodiment, the topical formulation is applied at least once daily for a period of about 4-12 weeks.
• compositions are contemplated for use in treating a subject that has mild to moderate Crohn’s disease or moderate to severe Crohn’s disease.
• compositions are contemplated for use in treating a subject gastrointestinal graft-vs-host disease, pouchitis, or mucositis.
• the dosing schedule for treating UC, IBD or other inflammatory disorders will depend, as can be appreciated, by factors well known in medical arts, including the dose of dmg compound in the formulation, the severity of the disorder, and the health of the patient.
• the methods comprise administering the composition at least about once daily, at least about twice daily, at least three times daily, or once daily, twice daily or three times daily.
• the composition is administered for a period of at least about 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 52 weeks or chronically.
• formulations that result in systemic exposure may be used to treat other autoimmune or auto-inflammatory diseases.
• autoimmune or auto-inflammatory diseases include but are not limited to ankylosing spondylitis, atopic dermatitis, Alzheimer’s disease, celiac disease, grave’s disease, lupus, multiple sclerosis, psoriasis, rheumatoid arthritis, Sjogren’s syndrome, type-1 and type-2 diabetes, vitiligo, or any of the diseases identified by the American Autoimmune Related Diseases Association in its Autoimmune Disease list viewable at aarda.org.
• formulations may treat oral diseases or diseases with oral manifestations such as bacterial-related diseases such as syphilis, Behcet’s disease, chronic aphthous stomatitis, erythema multiforme, eosinophillic esophagitis, MAGIC syndrome, mucous membrane pemphigoid, mucosal pemphigus vulgaris, Sweet syndrome or Wegner’s Granulomatosis.
• bacterial-related diseases such as syphilis, Behcet’s disease, chronic aphthous stomatitis, erythema multiforme, eosinophillic esophagitis, MAGIC syndrome, mucous membrane pemphigoid, mucosal pemphigus vulgaris, Sweet syndrome or Wegner’s Granulomatosis.
• compositions may be used to treat or prevent mucosal complications related to radiation therapy or chemotherapy such as chronic hemorrhagic radiation proctitis, diarrhea, xerostomia, mucositis, or dermatitis.
• the compositions e.g., the dosage form and formulations
• a higher dose is administered for initiation of treatment and a lower dose is administered for maintenance, in order to minimize long-term systemic exposure to the drug compounds.
• the initiation dose would be taken for about 8 weeks or until the patient’s symptoms abate and/or go into remission, followed by administration of a maintenance dose that is less than the initiation dose.
• a patient may increase the dose for a period of time corresponding to a flare in the disease, and then return to a lower maintenance dose.
• the oral dosage form or jar containing the oral dosage form may include a sensor that works as part of a compliance management system alerting the patient, pharmacist or physician via smartphone application or text message when to take a dose or in the event of a missed dose or when medication is running low.
• the dosage given to a patient or a patient’s eligibility for use would be determined after genotyping or screening a patient for polymorphisms in the ligand binding domain of the ary l hydrocarbon receptor or other cellular components needs for effective aryl hydrocarbon signaling.
• indigo 50 mg is extracted from Indigo naturalis and placed into a gelatin capsule along with magnesium stearate and microcrystalline cellulose for oral delivery.
• the compounds indigo and indirubin are synthetically prepared.
• the compounds are combined at a weight ratio of 60:40 and pressed into a solid core that is coated with an enteric polymer for oral delivery.
• HPMCP HP55 hydroxypropylmethylcellulose phthalate
• EUDRAGIT ® LI 00-55 methacrylic acid-ethyl acrylate copolymer
• 10 mg of synthetic indirubin is made in the form of an amorphous solid suspension made of a 1 : 1 mixture of povidone and HPMC HP55 is micronized and then suspended in an aersolizable foam and placed into a delivery device that can be inserted into the rectum to apply the foam for the treatment of proctitis or distal colitis.
• Solid Dispersion 1 The indirubin solution and the polymer solution were mixed to provide a mixture with an indirubimPVP weight ratio of 1:9. Solvent was removed by rotary evaporation at 50 °C. The resulting film was clear in color, indicating none of the indirubin was in dissolved in the solid PVP, and crystalline drug was observed. An image of the film is shown in FIG. 1A.
• Solid Dispersion 2 The indirubin solution and the polymer solution were mixed to provide a mixture with an indirubimPVP ratio of 1 :9. Solvent was reduced to 45% of original weight by rotary evaporation at 50 °C. The mixture was placed in a petri dish and dried under vacuum at 50 °C. The resulting film was clear in color, indicating none of the indirubin was in dissolved in the solid PVP, and crystalline drug was observed. An image of the film is shown in FIG. IB
• Synthetic crystalline indirubin was prepared as described in Comparative Example 1. It was dissolved in tetrahydrofuran by warming to 50 °C to form a solution with indirubin at a concentration of 1 mg/mL.
• Solid Dispersion 3 Polyvinylpyrrolidone (“PVP”; PLASDONETM K29/32) was dissolved in an 95% ethanol to form a 15% PVP polymer solution. The indirubin solution and the polymer solution were mixed to provide a mixture with an indirubimPVP weight ratio of 1 :9. Solvent was reduced to 45% of original weight by rotary evaporation at 50 °C. The mixture was placed in a petri dish and dried under vacuum at 50 °C. The resulting film was purplish in color, indicating some mdirubin was in dissolved in the solid PVP and in the form of a solid solution.
• PVP Polyvinylpyrrolidone
• Solid Dispersion 4 PVP (PLASDONETM K29/32) was dissolved in anyhdrous methanol to form a 15% PVP polymer solution. The indirubin solution and the polymer solution were mixed to provide a mixture with an indirubi PVP weight ratio of 1 :9. Solvent was reduced to 45% of original weight by rotary evaporation at 50 °C. The mixture was placed in a petri dish and dried under vacuum at 50 °C. The resulting film was purplish in color, indicating some indirubin was in dissolved in the solid PVP and in the form of a solid solution. An image of the film is show n in FIG. 2A.
• Solid Dispersion 5 PVP (PLASDONETM K29/32 was dissolved in anyhdrous methanol to form a 15% PVP polymer solution. The indirubin solution and the polymer solution were mixed to provide a mixture with an indirubimPVP ratio of 1 :9. Solvent was removed by rotary evaporation at 50 °C. The resulting film was purple with no crystalline indirubin observed indicating indirubin was in dissolved in the solid PVP and in the form of a solid solution. An image of the film is shown in FIG. 2B.
• Synthetic crystalline indirubin was prepared as described in Comparative Example 1. It w as dissolved in tetrahydrofuran by warming to 50 °C to form a solution with indirubin at a concentration of 1 mg/mL.
• the polymers listed below were separately dissolved in anyhdrous methanol to form a 15% polymer solution.
• the indirubin solution and the polymer solution were mixed to provide a mixture with an indirubin: polymer ratio of 1:9.
• Solvent was removed by rotary evaporation at 50 °C.
• the polymers were butylated methacrylate copolymer (EUDRAGIT ® EPO), methacrylic acid-ethyl acrylate copolymer (1 : 1) (EUDRAGIT ® LI 00-55), PVP (KOLLIDON ® VA 74), hydroxypropyl methylcellulose acetate succinate (HPMC-AS 912 F),
• HPMCP-HP55 hydroxypropylmethylcellulose phthalate
• POLYOXTM WSR-N10 polyethylene oxide
• PTHALAVINTM polyvinyl acetate phthalate
• poloxamer P188 KOLLIPHOR P188
• PVAc-PVCap- PEG SOLUPLUS ®
• the resulting films were observed for color and presence of crystalline indirubin.
• the films prepared with PVAc-PVCap- PEG and with polyvinylpyrrolidone-vinyl acetate copolymer (copovidone) were purple in color and with no crystalline indirubin observed, indicating indirubin was in dissolved in the solid polymer in amorphous form and in the form of a solid solution.
• Samples 1-3, 1-5, 1-7, and 1-12 had low crystalline content. These polymer and solvents were used to in a further study using a 20/80 or a 50/50 polymer
• Solid dispersions with synthetic indirubin were prepared for analysis by x-ray diffraction (XRD). Films of solid dispersions were cast directly onto zero background silicon sample holder slides. Films of indirubin: povidone dispersions were prepared at 10% and 5% indirubin load using the tetrahydrofuran/methanol solvation/evaporation preparation technique described in Example 11, Solid Dispersion 5. All other indirubin dispersions for this study were prepared at either 5% or 10% drug load as decribed in Example 13. All films were analyzed by x-ray diffraction, and the diffractograms are shown in FIGS. 3C-3M. FIG. 3A is an x-ray diffractogram for the zero background holder and FIG.
• 3B is an x-ray diffractogram for neat synthetic indirubin in tetrahydrofuran at 1 mg/mL, added to the zero background holder dropwise and allowed to dry completely and represent the expected results of a 10% indirubin load dispersion with 100% crystalline drug substance.
• Table 14-1 Analysis of XRD Diffractogram for Empty Zero Background Sample Holder (FIG. 3A)
• Table 14-3 Analysis of XRD Diffractogram of 10% indirubin in PVP dispersion (FIG. 3C)
• Table 14-4 Analysis of XRD Diffractogram of 5% indirubin in PVP dispersion (FIG. 3D)
• Table 14-7 Analysis of x-ray diffraction diffractogram of a dispersion of 10% indirubin in HPMC-AS912 Dispersion from THF and Methanol/Acetone (FIG. 3G)
• Table 14-9 Analysis of x-ray diffraction of a dispersion of 10% indirubin in HPMCP (HP55) from THF and
• Table 14-10 Analysis of x-ray diffraction of a dispersion of 5% indirubin in HPMCP (HP55) from THF and
• Table 14-11 Analysis of x-ray diffraction of a dispersion of 10% indirubin in polyvinyl acetate phthalate (PVAP) from THF/methanol (FIG. 3K)
• PVAP polyvinyl acetate phthalate
• Table 14-13 Analysis of x-ray diffraction of a dispersion of 10% indirubin in PVAc-PVCap- PEG, (SOLUPLUS ® ) from THF (FIG 3M)
• Solid amorphous dispersions of synthetic indimbin in six different hydrophilic carrier polymers - povidone, PVAc-PVCap-PEG, (SOLUPLUS ® ), copovidone, HPMC-AS, HPMCP and polyvinyl acetate phthalate (PVAP) with indirubin to polymer ratios of 1:9 or 0.5 to 9.5 were prepared as described in Example 13. For comparison, Indigo naturalis and crystalline synthetic indirubin were also tested.
• test articles were normalized to a total indirubin of 2 mg and added to 500 mL of fasted-state simulated intestinal fluid (FaSSIF) medium consisting of 3 mM taurocholate, 0.75 mM phospholipids, 148 mM sodium, 106 mM chloride, and 29 mM phosphate at pH 6.5.
• FaSSIF fasted-state simulated intestinal fluid
• Six replicates of each test article were assessed under the following testing conditions: mixing with USP #2 paddles at 100 RPM at 37 °C with sampling of 5 mL at each time point and filtration through a 10 pm filter.
• the amount of indirubin in solution was determined with an HPLC method specific for indirubin that did not display interference from indigo or the various polymers.
• the mean amount of indirubin in solution at each time point was determined, and is shown in Table 1 in units of pg/L and in Table 2 as a percentage, referred to a %Q, of measured amount (mass) of indirubin in solution divided by the theoretical maximum amount (mass) of indirubin in solution.
• the percent of 14 C provides a measure of the amount of carbon in the molecule originating from fossilized hydrocarbon based starting materials which are expected to have a very low 14 C content in comparison to material isolated from recently living sources which would be expected to have close to an atmospheric amount of 14 C.
• the amount of 14 C in a sample changes slowly as the half-life of 14 C is 5,730 years.
• this data provides a clear method for distinguishing between synthetic indirubin derived from fossilized hydrocarbon starting materials and naturally derived indirubin based on the 14 C content.
• synthetic indirubin has a 14 C content of less than about 0.9 ppt 14 C.
• synthetic indirubin has a fossil carbon content of greater than 10%.
• Indirubin, indigo and Indio naturalis were incubated for 24 hours with reporter cells made from human Huh7 cells expressing human AhR and ARNT with luciferase expressed behind a genetic response elements that responds to dimerized AhR/ ARNT. After incubation, the medium was aspirated and a detection reagent was added followed by a measurement of the relative luminescent units compared to a negative control of DMSO. Data is shown in FIG. 4.
• Each patient serves as his or her own control to establish the degree of abnormality of the stool frequency.
• the daily bleeding score represents the most severe bleeding of the day.

Landscapes

• Health & Medical Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=70775588

Family Applications (1)

Country Status (10)

Cited By (2)

Families Citing this family (4)

Citations (4)

Family Cites Families (5)

• 2020
  • 2020-05-01 US US16/865,183 patent/US20200345645A1/en not_active Abandoned
  • 2020-05-01 CN CN202080042143.2A patent/CN114340600A/zh active Pending
  • 2020-05-01 EP EP20727107.3A patent/EP3962458A1/en not_active Withdrawn
  • 2020-05-01 TW TW109114724A patent/TW202106296A/zh unknown
  • 2020-05-01 JP JP2021565743A patent/JP2022531012A/ja active Pending
  • 2020-05-01 WO PCT/US2020/031174 patent/WO2020227151A1/en not_active Ceased
  • 2020-05-01 AU AU2020269379A patent/AU2020269379A1/en not_active Abandoned
  • 2020-05-01 CA CA3136081A patent/CA3136081A1/en active Pending
  • 2020-05-01 KR KR1020217039676A patent/KR20220044435A/ko not_active Withdrawn
  • 2020-05-01 MX MX2021013386A patent/MX2021013386A/es unknown
• 2022
  • 2022-04-22 US US17/727,510 patent/US20220249382A1/en not_active Abandoned
• 2025
  • 2025-02-14 US US19/053,798 patent/US20250255820A1/en active Pending

Patent Citations (4)

Non-Patent Citations (11)

Also Published As

Similar Documents

Legal Events